News outlets report on French drugmaker Sanofi’s announcement that its experimental dengue vaccine has reduced disease cases in a large clinical trial.

Bloomberg News: Sanofi Dengue Vaccine Works on All Four Types in Study
“Sanofi’s experimental vaccine against dengue protected children with all four types of the mosquito-borne illness in a clinical test, a stronger result than shown in a smaller study this year…” (Serafino, 9/3).

Reuters: Final trial confirms efficacy of Sanofi’s dengue vaccine
“French drugmaker Sanofi, developing the first vaccine against dengue fever, said its product reduced disease cases by 60.8 percent in a large final clinical trial. Sanofi has invested more than 1.3 billion euros ($1.7 billion) in the project, undertaking two decades of research on the world’s fastest-growing tropical disease…” (Huet, 9/3).